8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 31, 2026·SEC
OS Therapies Incorporated(OSTX)Earnings, Financials & Key Ratios
OSTX•NYSE
$1.88
Price updated Jun 27, 2026
AboutOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Show more
- Revenue$0
- EBITDA-$28M-316.1%
- Net Income-$29M-223.7%
- EPS (Diluted)-0.98-88.5%
OSTX Price & Volume
OS Therapies Incorporated (OSTX) stock price & volume — 10-year historical chart
Loading chart...
Escalating Clinical Costs Challenge Capital Structure Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"OS Therapies faces a precarious fundamental outlook as it advances the OST-HER2 immunotherapy program, characterized by a total lack of revenue and accelerating quarterly operating losses that reached $10.2 million in 2026Q1. While the company reports a significant cash position of $917.6 million, the presence of $1.3 billion in total debt against only $7.3 million in total assets suggests severe balance sheet distortion. Investors should monitor the sustainability of this clinical runway, as the firm's reliance on external financing and non-cash accounting entries, such as the $4.3 billion stock-based compensation spike in 2025Q4, obscures the true economic cost of its development pipeline."
Verdict Logic
the company's extreme balance sheet distortion, evidenced by $1.3 billion in total debt against only $7.3 million in total assets, presents an unacceptable risk profile for long-term capital preservation.
OSTX Growth Metrics
OS Therapies Incorporated (OSTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-212.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-124.93%
Return on Capital
10 Years-747.55%
5 Years-747.55%
3 Years-747.55%
Last Year-
OSTX Recent Earnings
OS Therapies Incorporated (OSTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/12 qtrs (0%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.27-58.8%
$0.17
Rev
—
$971,000
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.35-157.4%
$0.14
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.21-31.3%
$0.16
Rev
—
—
Q3 2025
Aug 19, 2025Metric
Actual
Est
EPS
$0.19-26.7%
$0.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.27vs $0.17-58.8% | —vs $971,000 |
| Q2 2026 | Mar 31, 2026 | $0.35vs $0.14-157.4% | — |
| Q4 2025 | Nov 14, 2025 | $0.21vs $0.16-31.3% | — |
| Q3 2025 | Aug 19, 2025 | $0.19vs $0.15-26.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for OS Therapies Incorporated (OSTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.88 | $83.73M | -1.92 | — | — | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $3.25 | $354.88M | -1.62 | — | — | -70.79% | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $1.02 | $129.73M | -0.91 | 14.85% | -173.02% | — | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — |
Compare OSTX vs Peers
OS Therapies Incorporated (OSTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OSTX SEC Filings & Documents
OS Therapies Incorporated (OSTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OSTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OSTX Frequently Asked Questions
OS Therapies Incorporated (OSTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is OSTX profitable?
OS Therapies Incorporated (OSTX) reported a net loss of $35.3M for fiscal year 2025.
Dividend & Returns
What is OS Therapies Incorporated's free cash flow?
OS Therapies Incorporated (OSTX) had negative free cash flow of $15.7M in fiscal year 2025, likely due to heavy capital investments.